Dewpoint Therapeutics' Ann Boija Delivers Featured Presentation at Discovery on Target 2026
Ann Boija, Ph.D., Chief Scientific Officer of Dewpoint Therapeutics, delivered a featured presentation on condensate-modulating therapeutics at the 24th Annual Discovery on Target conference in Boston, held September 28 to October 1, 2026.
Dewpoint is a clinical-stage biotechnology company pioneering condensate-modulating therapeutics. Its lead program, DPTX3186, a beta-catenin condensate modulator, entered a Phase 1a/2a trial in advanced solid tumors earlier this year, and the company presented preclinical data on an oral MYC condensate modulator at AACR 2026 in April.
